Wednesday, April 01, 2020 2:20:38 PM
Reason for today's drop. Looking like it is recovering a bit:
01:55 PM EDT, 04/01/2020 (MT Newswires) -- The US Food and Drug Administration said on Wednesday it is requesting manufacturers withdraw all prescription and over-the-counter ranitidine drugs, commonly known as Zantac, from the market immediately following an ongoing probe of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications.
"The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity," the regulator said. NDMA is a probable human carcinogen, a substance that could cause cancer.
GlaxoSmithKline (GSK), the initial maker of Zantac for heartburn and indigestion in the 1980s, later sold the US brand rights to Sanofi. It has since lost patent protection is is produced by several generic drug companies. Sanofi recalled branded Zantac products in October. GSK was down more than 1% in afternoon trading. Shares of other Zantac-makers were also sharply lower, including Mylan (MYL), Sanofi (SNY) and Teva (TEVA), amid a fall in broader markets and health care stocks.
01:55 PM EDT, 04/01/2020 (MT Newswires) -- The US Food and Drug Administration said on Wednesday it is requesting manufacturers withdraw all prescription and over-the-counter ranitidine drugs, commonly known as Zantac, from the market immediately following an ongoing probe of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications.
"The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity," the regulator said. NDMA is a probable human carcinogen, a substance that could cause cancer.
GlaxoSmithKline (GSK), the initial maker of Zantac for heartburn and indigestion in the 1980s, later sold the US brand rights to Sanofi. It has since lost patent protection is is produced by several generic drug companies. Sanofi recalled branded Zantac products in October. GSK was down more than 1% in afternoon trading. Shares of other Zantac-makers were also sharply lower, including Mylan (MYL), Sanofi (SNY) and Teva (TEVA), amid a fall in broader markets and health care stocks.
Recent TEVA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 08:40:45 PM
- Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:00:20 AM
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
